Shareholders of Selecta Biosciences, Inc. (NASDAQ:SELB) will be pleased this week, given that the stock price is up 12% to US$4.32 following its latest second-quarter results. Revenues beat ...
Selecta Bio saw 4 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Selecta Bio's stock price’s past reactions to earnings here. According to InvestingPro, Selecta Bio's ...
Selecta Biosciences Inc. SELB is engaged in developing tolerogenic therapies that selectively mitigate unwanted immune responses. The company’s lead pipeline candidate SEL-212 is a combination of its ...
Selecta Bio saw 2 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Selecta Bio's stock price’s past reactions to earnings here. According to InvestingPro, Selecta Bio's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results